These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36429096)

  • 1. Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies.
    Braconi D; Geminiani M; Psarelli EE; Giustarini D; Marzocchi B; Rossi R; Bernardini G; Spiga O; Gallagher JA; Le Quan Sang KH; Arnoux JB; Imrich R; Al-Sbou MS; Gornall M; Jackson R; Ranganath LR; Santucci A
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project.
    Braconi D; Giustarini D; Marzocchi B; Peruzzi L; Margollicci M; Rossi R; Bernardini G; Millucci L; Gallagher JA; Le Quan Sang KH; Imrich R; Rovensky J; Al-Sbou M; Ranganath LR; Santucci A
    Osteoarthritis Cartilage; 2018 Aug; 26(8):1078-1086. PubMed ID: 29852277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.
    Spreafico A; Millucci L; Ghezzi L; Geminiani M; Braconi D; Amato L; Chellini F; Frediani B; Moretti E; Collodel G; Bernardini G; Santucci A
    Rheumatology (Oxford); 2013 Sep; 52(9):1667-73. PubMed ID: 23704321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloidosis in alkaptonuria.
    Millucci L; Braconi D; Bernardini G; Lupetti P; Rovensky J; Ranganath L; Santucci A
    J Inherit Metab Dis; 2015 Sep; 38(5):797-805. PubMed ID: 25868666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkaptonuria is a novel human secondary amyloidogenic disease.
    Millucci L; Spreafico A; Tinti L; Braconi D; Ghezzi L; Paccagnini E; Bernardini G; Amato L; Laschi M; Selvi E; Galeazzi M; Mannoni A; Benucci M; Lupetti P; Chellini F; Orlandini M; Santucci A
    Biochim Biophys Acta; 2012 Nov; 1822(11):1682-91. PubMed ID: 22850426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative proteomics in alkaptonuria provides insights into inflammation and oxidative stress.
    Braconi D; Bernardini G; Paffetti A; Millucci L; Geminiani M; Laschi M; Frediani B; Marzocchi B; Santucci A
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):271-280. PubMed ID: 27590860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient.
    Millucci L; Ghezzi L; Paccagnini E; Giorgetti G; Viti C; Braconi D; Laschi M; Geminiani M; Soldani P; Lupetti P; Orlandini M; Benvenuti C; Perfetto F; Spreafico A; Bernardini G; Santucci A
    Mediators Inflamm; 2014; 2014():258471. PubMed ID: 24876668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease.
    Cicaloni V; Spiga O; Dimitri GM; Maiocchi R; Millucci L; Giustarini D; Bernardini G; Bernini A; Marzocchi B; Braconi D; Santucci A
    FASEB J; 2019 Nov; 33(11):12696-12703. PubMed ID: 31462106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins.
    Braconi D; Millucci L; Bernini A; Spiga O; Lupetti P; Marzocchi B; Niccolai N; Bernardini G; Santucci A
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):135-146. PubMed ID: 27865997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoskeleton Aberrations in Alkaptonuric Chondrocytes.
    Geminiani M; Gambassi S; Millucci L; Lupetti P; Collodel G; Mazzi L; Frediani B; Braconi D; Marzocchi B; Laschi M; Bernardini G; Santucci A
    J Cell Physiol; 2017 Jul; 232(7):1728-1738. PubMed ID: 27454006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
    Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
    Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    Osteoporos Int; 2021 May; 32(5):927-938. PubMed ID: 33118050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of secondary amyloidosis in alkaptonuria.
    Millucci L; Ghezzi L; Bernardini G; Braconi D; Lupetti P; Perfetto F; Orlandini M; Santucci A
    Diagn Pathol; 2014 Sep; 9():185. PubMed ID: 25567001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty.
    Ranganath LR; Khedr M; Norman BP; Hughes JH; Imrich R; Arnoux JB; Olsson B; Rudebeck M; Gallagher JA; Bou-Gharios G
    Mol Genet Metab Rep; 2024 Sep; 40():101097. PubMed ID: 38846518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.